Lycia Therapeutics, Inc. Common Stock (LYCA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.59B. Nama's AI scorecard rates it Sell, 4.1 out of 10.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 6, 2026.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-16.4%
How far the last close sits under the highest price of the past five years.
Nama's AI scorecard currently rates Lycia Therapeutics, Inc. Common Stock Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
Is LYCA Shariah compliant?
Nama's AAOIFI-style screen reads Lycia Therapeutics, Inc. Common Stock as Can't Tell. A figure the screen needs is missing, so it can't tell.